On-demand, rental electric scooters are seen as a way of easing the pressure on public transport systems during the COVID-19 crisis. Although e-scooters have been in the UK for some time now, e-scooter rentals only became legal on UK roads on 4 July 2020. Up until 4 July 2020, it was illegal to use e-scooters on any public road or footpath in the UK. Even with the change in the law, it is still illegal to use a privately owned e-scooter on a public road or a footpath in the UK. This article takes a look at the patent portfolios of some of the major players in e-scooter rentals.
Insights: Technical Insights
Artificial intelligence is increasingly an important tool in industry. Not just in computer science but in almost all fields of industry. And where an AI innovation provides a benefit to users, many would like to protect it with a patent. The European Patent Office (EPO) recognises this. In 2017 the EPO published a study on the ‘Fourth Industrial Revolution’ that identified AI as a key enabling technology. As we reported previously, the EPO has held a conference discussing the patentability of AI. And the EPO has recently announced that their Berlin branch is to become a centre of expertise in AI. So it is worth looking at how AI inventions can be patented in Europe.
We have just finished watching the oral proceedings before the EPO’s Enlarged Board of Appeal (EBA) on case G1/19 concerning the patentability of computer simulations. We were not alone – some 1,600 people signed up to watch today’s oral proceedings by live stream. Unfortunately (but not unexpectedly) no decision was announced during the proceedings. However, we did get to hear some of the EBA’s thoughts on the issues.
The Automotive Transformation Fund – a new funding competition to move the automotive sector to zero emissions
Innovate UK – together with the Advanced Propulsion Centre (APC), the Department for Business, Energy, and Industrial Strategy (BEIS), and the Department for International Trade (DIT) – have opened a new funding competition: The Automotive Transformation Fund. This funding competition can be seen as part of the UK government’s broader Road to Zero Strategy which seeks to reduce vehicle emissions to zero by 2050, and, perhaps more ambitiously, aims for at least half of new cars to be “ultra-low emission” by 2030.
In his recent article, Robin Ellis summarised the key take-home messages from the UK Supreme Court judgement in Regeneron v Kymab.In this article Andrew Carridge takes a more in-depth look into the concept of a ‘principle capable of general application’, exploring when broad claims may be justified and when claims may legitimately cover as yet undiscovered embodiments.
Following our recent blog on the shortlist of finalists for the 2020 MacRobert Award, the Royal Academy of Engineering has now announced that the winner of the 2020 MacRobert Award is JCB, with the 19C-1E electric digger.
On 9th July 2020, the Court of Justice of the European Union (CJEU) handed down their emphatic judgement concerning Supplementary Protection Certificates (SPCs) in Santen v INPI (C‑673/18). For those interested in the details and history of the case they can be found in my earlier blog, published in January, where I discussed the Advocate General’s preliminary and non-binding opinion. As far as this judgement is concerned the conclusion is clear: “a marketing authorisation (MA) cannot be considered to be the first MA … where it covers a new therapeutic application of an active ingredient, or of a combination of active ingredients, and that active ingredient or combination has already been the subject of an MA for a different therapeutic application” – emphasis added Put another way, the CJEU has decided that the literal wording of Articles 1(a), (b) and 3(d) of the SPC Regulation mean what they say. The previous CJEU decision in Neurim is consigned to the scrapheap.
On 24th June 2020 the UK Supreme Court handed down their judgement addressing the question of breadth of claim and sufficiency. Although the decision is well written, its background is in biotechnology which is likely to dissuade a lot of people from reading it and/or understanding its broader implications. So with this in mind, here’s my attempt to explain Regeneron v Kymab sufficiency using … TELEPORTATION.